Synonym
CH 66; CH-66; CH66; Piv-his-pro-phe-leu(OH)leu-tyr-tyr-ser-NH2;
IUPAC/Chemical Name
(2S)-N-((2S)-1-((1-(((S)-1-(((S)-1-(((S)-1-(((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-hydroxy-4-methylpentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-1-(pivaloyl-L-histidyl)pyrrolidine-2-carboxamide
InChi Key
IOODFRUCBCPLAP-WRPOBCEFSA-N
InChi Code
OCC[S=N]H(C(N)=O)NC(C[S=I]H(CC[12]=CC=C(O)C=C@12)NC(C[S=I]H(CC[24]=CC=C(O)C=C@24)NC(C[S=I]H(CC(C)C)NC(O)C(NC(C[S=I]H(CC[52]=CC=CC=C@52)NC(C[61:S=I]HN(C(C[S=I]H(CC[70]=CNC=N@70)NC(C(C)(C)C)=O)=O)CCC@61)=O)=O)CC(C)C)=O)=O)=O
SMILES Code
OC[C@@H](C(N)=O)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CC(C)C)NC(O)C(NC([C@H](CC3=CC=CC=C3)NC([C@H]4N(C([C@H](CC5=CNC=N5)NC(C(C)(C)C)=O)=O)CCC4)=O)=O)CC(C)C)=O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,124.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dealwis CG, Frazao C, Badasso M, Cooper JB, Tickle IJ, Driessen H, Blundell TL, Murakami K, Miyazaki H, Sueiras-Diaz J, et al. X-ray analysis at 2.0 A resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen. J Mol Biol. 1994 Feb 11;236(1):342-60. PubMed PMID: 8107115.
2: Kvist S, Mulvany MJ, Aalkjaer C. Studies of the renin-angiotensin system in the wall of rat femoral resistance vessels. Eur J Pharmacol. 1991 May 30;198(1):77-83. PubMed PMID: 1915579.
3: Guruprasad K, Blundell TL, Xie S, Green J, Szafranska B, Nagel RJ, McDowell K, Baker CB, Roberts RM. Comparative modelling and analysis of amino acid substitutions suggests that the family of pregnancy-associated glycoproteins includes both active and inactive aspartic proteinases. Protein Eng. 1996 Oct;9(10):849-56. PubMed PMID: 8931124.
4: Kervinen J, Törmäkangas K, Runeberg-Roos P, Guruprasad K, Blundell T, Teeri TH. Structure and possible function of aspartic proteinases in barley and other plants. Adv Exp Med Biol. 1995;362:241-54. Review. PubMed PMID: 8540324.
5: Dhanaraj V, Dealwis CG, Frazao C, Badasso M, Sibanda BL, Tickle IJ, Cooper JB, Driessen HP, Newman M, Aguilar C, et al. X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature. 1992 Jun 11;357(6378):466-72. PubMed PMID: 1608447.
